Kenvue Inc.
KVUE Consumer Defensive Household & Personal Products NYSE
$17.63
$-0.18 (-0.98%)
Open: $17.79 | High: $17.89 | Low: $17.58 | Prev Close: $17.80
Market Cap: $33.77B
Volume: 20.8M | Avg: 43.0M
Last updated: January 26, 2026 at 06:03 PMFeatured In
This stock appears in the following dashboards:
Options Activity for KVUE
Options Screener Data
| Type | Strike | Expiration | Premium | Premium Yield | Call Vol | Put Vol | P/C Ratio | Rating |
|---|---|---|---|---|---|---|---|---|
| N/A | $N/A | N/A | $N/A | N/A% | N/A | N/A | N/A | N/A/10 |
Puts/Calls Activity
| Type | Strike | Expiration | Premium | Volume | ROI % | Breakeven | Delta |
|---|---|---|---|---|---|---|---|
| N/A | $N/A | N/A | $N/A | N/A | N/A% | $N/A | N/A |
Investment Rating
Neutral
Overall Score: 60/100
Rating Breakdown:
Stock Score Analysis
Stock Score: 430
Comprehensive Quality Assessment
Component Breakdown:
Valuation Metrics
| P/E Ratio | 23.50 |
| P/B Ratio | 3.18 |
| P/S Ratio | 2.25 |
| EPS | $0.75 |
| Beta | 0.55 |
| Shares Outstanding | 1.92B |
| 52-Week High | $25.17 |
| 52-Week Low | $14.02 |
| SMA 50 | $17.02 |
| SMA 200 | $19.53 |
| Dividend Yield | 4.68% |
| Annual Dividend | $0.83 |
| Next Earnings | February 05, 2026 12:00 PM ET |
Financial Ratios
| Gross Margin | 58.1% |
| Operating Margin | 15.7% |
| Net Margin | 9.5% |
| ROE | 14.0% |
| ROA | 5.3% |
| Debt/Equity | 0.86 |
| Current Ratio | 0.98 |
| Quick Ratio | 0.69 |
Balance Sheet
| Total Assets | $25.60B |
| Total Liabilities | $15.93B |
| Total Equity | $9.67B |
|
|
|
| Cash | $1.07B |
| Total Debt | $8.72B |
| Net Debt | $7.65B |
Income Statement
| Revenue | $15.46B |
| Gross Profit | $8.96B |
| Operating Income | $1.84B |
| Net Income | $1.03B |
|
|
|
| EBITDA | $2.47B |
| Revenue/Share | $7.82 |
Cash Flow
| Operating CF | $1.77B |
| CapEx | $434.00M |
| Free Cash Flow | $1.33B |
|
|
|
| Book Value/Share | $5.54 |
| Tangible Book/Share | $-3.92 |
| Equity/Share | $5.54 |
Technical Indicators
| RSI (14) | 50.00 Neutral |
| MACD |
0.00
Signal: 0.00
|
| Volatility | 0.00% |
| Trading Signal | Neutral |
Performance & Returns
Insufficient historical data
Insufficient historical data (need 200+ days, have 0)Sector Comparison (Consumer Defensive)
| Metric | KVUE | Sector Avg | Percentile |
|---|---|---|---|
| P/E Ratio | 23.5 | 17.1 | 48% |
| P/B Ratio | 3.18 | -14.78 | 45% |
| ROE (%) | 13.95% | 59.35% | 39% |
| Net Margin (%) | 9.55% | 6.81% | 52% |
| Stock Score | 430 | 429.0 | 48% |
Technical Analysis
| Ticker | Close | SMA 5 | SMA 8 | SMA 13 | SMA 50 | SMA 200 | RSI (14) | MACD | Volatility (%) | Volume | Signal | SMA Decision |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| KVUE | $17.63 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | 50.00 | 0.00 | 0.00% | 0 | Neutral | Mixed |
Candlestick Patterns
There wasn't any recognizable pattern for the KVUE stock
News Sentiment
| 📊 Ticker | 📰 Headline | 💭 Sentiment | 📡 Source | 🔗 URL |
|---|---|---|---|---|
| KVUE | Kimberly-Clark Posts Higher Profit Ahead of Kenvue Vote | Positive | wsj.com | Read More |
| KVUE | Investment House LLC Reduces Position in Kenvue Inc. $KVUE | Neutral | defenseworld.net | Read More |
| KVUE | Callahan Advisors LLC Takes Position in Kenvue Inc. $KVUE | Neutral | defenseworld.net | Read More |
| KVUE | Paracetamol/Tylenol in pregnancy is safe, says research prompted by Trump autism claims | Neutral | reuters.com | Read More |
| KVUE | ISS recommends shareholders approve Kimberly-Clark's planned Kenvue deal | Neutral | reuters.com | Read More |
Recent Insider Trading
| Date | Insider | Position | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-01-01 | Curado Gomes de Lemos Leonardo | officer: Group President LATAM | SELL | 12818 | $23.96 | $307119 |
| 2025-12-15 | Perry Kirk | officer: Chief Executive Officer | SELL | 56007 | $17.21 | $963880 |
| 2025-12-15 | De Jesus Carlos | officer: Group President North America | BUY | 483870 | $17.21 | $8327403 |
| 2025-12-15 | Dyer Russell | officer: Chief Corp. Affairs Officer | SELL | 1103 | $17.21 | $18983 |
| 2025-12-15 | Dyer Russell | officer: Chief Corp. Affairs Officer | SELL | 1408 | $17.21 | $24232 |
| 2025-12-15 | Perry Kirk | officer: Chief Executive Officer | SELL | 66614 | $17.21 | $1146427 |
| 2025-12-15 | Tillett Caroline | officer: Chief Scientific Officer | SELL | 1725 | $17.21 | $29687 |
| 2025-12-15 | Tillett Caroline | officer: Chief Scientific Officer | SELL | 2251 | $17.21 | $38740 |
| 2025-12-15 | Tillett Caroline | officer: Chief Scientific Officer | SELL | 1532 | $17.28 | $26473 |
| 2025-12-15 | Tillett Caroline | officer: Chief Scientific Officer | SELL | 11846 | $17.28 | $204699 |
Company Information
Kenvue Inc. operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, and other products under the Tylenol, Nicorette, and Zyrtec brands. The Skin Health and Beauty segment provides face and body care, hair care, and sun and other care products under the Neutrogena, Aveeno, and OGX brand names. The Essential Health segment offers oral and baby, women's health, and wound care products under the Listerine, Johnson's, Band-Aid, and Stayfree brands. The company was incorporated in 2022 and is headquartered in Skillman, New Jersey. Kenvue Inc. operates as a subsidiary of Johnson & Johnson.
| CEO | Kirk L. Perry |
| Employees | 22000 |
| Country | US |
| IPO Date | 2023-05-04 |
| Exchange | NYSE |
| Website | https://www.kenvue.com |
| Sector | Consumer Defensive |
| Industry | Household & Personal Products |
Similar Stocks (Consumer Defensive - Household & Personal Products)
Rating Metrics Explained
DCF Score (Discounted Cash Flow)
Measures the intrinsic value of the stock based on projected future cash flows. A higher score indicates the stock is undervalued relative to its DCF valuation.
ROE Score (Return on Equity)
Evaluates how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better profitability and management effectiveness.
ROA Score (Return on Assets)
Measures how efficiently a company uses its assets to generate profit. A higher ROA means better asset utilization and operational efficiency.
D/E Score (Debt-to-Equity)
Assesses the company's financial leverage and risk. Lower debt-to-equity ratios indicate less financial risk and better balance sheet health.
P/E Score (Price-to-Earnings)
Compares stock price to earnings per share. A lower P/E ratio may indicate the stock is undervalued, while a higher ratio could suggest overvaluation or growth expectations.
P/B Score (Price-to-Book)
Compares market price to book value per share. Lower P/B ratios may indicate undervaluation relative to the company's net asset value.
Rating Recommendations:
Each metric is scored on a scale of 1-5, where the scores are determined by comparing the company's performance against industry benchmarks and historical data:
-
Strong Buy (5/5): Excellent score - strong positive indicator
- The metric significantly outperforms industry averages (top 20% of companies)
- Indicates exceptional financial health or attractive valuation in that category
-
Buy (4/5): Good score - positive indicator
- Above-average performance (top 40% of companies)
- Shows strong fundamentals with room for improvement
-
Neutral (3/5): Average score - neutral indicator
- Performance in line with industry median (middle 20%)
- Neither significantly positive nor negative signal
-
Sell (2/5): Below average - negative indicator
- Below-average performance (bottom 40% of companies)
- Suggests weakness in this particular metric
-
Strong Sell (1/5): Poor score - strong negative indicator
- Significantly underperforms industry (bottom 20%)
- Indicates potential risk or overvaluation in that category